MarketCap
Facebook
X
TelegramAnnual report 2024
added 04-25-2026
Nymox Pharmaceutical Corporation ROCE Ratio 2011-2026 | NYMX
Annual ROCE Ratio Nymox Pharmaceutical Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 2471.15 | -466.37 | -386.12 | -151.97 | 1057.95 | -1866.73 | 1148.01 | 154.3 | 155.09 | 395.85 | -326.71 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2471.15 | -1866.73 | 198.59 |
Quarterly ROCE Ratio Nymox Pharmaceutical Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -208.09 | -416.17 | -500.73 | 19949.03 | 19938.25 | 20135.55 | 20495.39 | 81.92 | 37.57 | 3.99 | -340.01 | -141.95 | -213.45 | -240.6 | -240.03 | 114.95 | 114.95 | 186.45 | 254.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 20495.39 | -500.73 | 4158.51 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-299.89 | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
-27.78 | - | 1.35 % | $ 17.8 M |  China |
 |
Amphastar Pharmaceuticals
AMPH
|
17.8 | $ 16.88 | -2.43 % | $ 789 M |  USA |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | USA |
 |
Compugen Ltd.
CGEN
|
23.38 | $ 2.79 | -8.09 % | $ 261 M |  Israel |
 |
Coherus BioSciences
CHRS
|
-296.87 | $ 1.6 | -2.15 % | $ 187 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B | France |
 |
AstraZeneca PLC
AZN
|
16.47 | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-35.64 | $ 7.56 | -3.45 % | $ 207 M | Israel |
 |
Athira Pharma
ATHA
|
-368.0 | - | - | $ 269 M | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
-41.41 | - | 0.74 % | $ 768 M | Israel |
 |
Galera Therapeutics
GRTX
|
-63.97 | - | -32.59 % | $ 7.61 M | USA |
 |
Esperion Therapeutics
ESPR
|
-19.96 | $ 3.13 | 0.32 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
40.35 | $ 50.41 | -1.36 % | $ 13.7 B | USA |
 |
Fortress Biotech
FBIO
|
-140.8 | $ 2.43 | 5.65 % | $ 67.8 M | USA |
 |
Midatech Pharma plc
MTP
|
-71.74 | - | -18.52 % | $ 27.3 M | Britain |
|
Forte Biosciences
FBRX
|
-115.85 | $ 23.1 | -3.57 % | $ 299 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-10.46 | $ 9.76 | 5.63 % | $ 279 M | USA |
 |
AbCellera Biologics
ABCL
|
-16.8 | $ 4.09 | -7.05 % | $ 1.22 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
-151.88 | $ 1.59 | - | $ 423 M | Britain |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
BioNTech SE
BNTX
|
-7.08 | $ 89.16 | -3.08 % | $ 21.5 B | Germany |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.5 | - | - | $ 231 M | USA |
 |
Galectin Therapeutics
GALT
|
15.7 | $ 2.22 | -5.74 % | $ 142 M | USA |
 |
Gilead Sciences
GILD
|
44.14 | $ 130.07 | -1.51 % | $ 162 B | USA |
 |
Genmab A/S
GMAB
|
31.74 | $ 26.8 | -0.37 % | $ 1.73 B |  Danmark |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 3.41 | -2.25 % | $ 5.61 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-76.42 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
Grifols, S.A.
GRFS
|
6.19 | $ 7.74 | -0.64 % | $ 5.26 B |  Spain |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
-0.65 | $ 0.72 | -1.05 % | $ 32.9 M | Israel |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Eton Pharmaceuticals
ETON
|
-3.23 | $ 29.69 | -0.92 % | $ 799 M | USA |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
-116.14 | - | - | $ 28.6 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 21.51 | -0.3 % | $ 2.74 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-252.54 | - | 3.16 % | $ 1.9 M | USA |